Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT04463251

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
R-Pharm Overseas, Inc. (from the registry)
Registry
  • NCT NCT04463251
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04463251. Randomized; double masking; primary purpose treatment. Start 2020-12-07 (actual); primary completion 2021-11-03 (actual). Results posted on 2024-01-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Condition
Acute ST Segment Elevation Myocardial Infarction
Intervention (Biological)
RPH-104 80 mg
Intervention (Drug)
Placebo
Lead sponsor
R-Pharm Overseas, Inc. (class: industry)
Collaborator
Cromos Pharma LLC (class: industry)
Collaborator
Data Management 365 (class: industry)
Collaborator
Keystat, LLC (class: industry)
Collaborator
R-Pharm (class: industry)
Collaborator
K-Research, LLC (class: industry)

Record details

Record id
cardio:ct-nct04463251
Content hash
3c9d6be0566030ae740513f9c1a3f2e19d8838a73c8556c7d0793b451f6a8f8a